-- 中部電力は火曜日、2025年通年の発電量が9.2テラワット時(TWh)となり、前年の9.7TWhから減少したと発表した。 水力発電量は前年の9.3TWhから8.8TWhに減少した一方、その他の再生可能エネルギー発電量は400GWhで横ばいだった。 エネルギー関連サービスを提供するミライズ事業部は、2025年に109.0TWhの電力を販売し、2024年の107.9TWhから増加した。しかし、燃料費調整費の減少により、営業収益は3.5%減の2兆8590億円(179億2000万ドル)となった。 送電網事業部は、2025年に中部地方で123.9TWhの電力需要を供給し、前年の124.5TWhから減少した。関連する営業収益も3.6%減の9,286億3,000万円となった。 「現時点では、中部地方の電力需要への影響は限定的です。しかし、中東情勢の緊張が高まり長期化すれば、原油をはじめとするエネルギー源の供給不安から、中部地方の電力需要に影響が出る可能性があります」と同社は述べた。 同社は、燃料価格や卸売電力市場価格の不確実性を理由に、2027年3月期決算の業績予想を公表しなかった。
Related Articles
Research Alert: Sherwin-willams Q1 Eps Tops Expectations
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:SHW posted Q1 adjusted EPS of $2.35 versus $2.25 prior year, beating our $2.17 estimate and $2.27 consensus view. Net sales advanced 6.8% Y/Y to $5.67B, exceeding our 4.0% growth forecast, led by the Suvinil acquisition, favorable FX, and modest volume gains. The company demonstrated solid operational execution, with Paint Stores same-store sales improving to 2.4% from 1.2% in the prior year and Consumer Brands posting 19.2% growth, though North American DIY demand remained soft. Management maintained FY2026 guidance of low- to mid-single-digit sales growth with adjusted EPS projected at $11.50-$11.90, representing ~2.4% growth at the midpoint. Gross margin expanded 90bps to 49.1% on moderating raw material costs and improved pricing, though SG&A rose 9.8% as Suvinil integration costs pressured margins. The company also continued its shareholder return program in Q1, deploying $772.7M through dividends and share repurchases, despite acknowledging persistent macroeconomic uncertainty.
Research Alert: Ecolab Posts Solid Q1; Accelerated Growth; Near-term Margin Pressure Expected
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ecolab reported Q1 sales of $4.1B (+10% Y/Y), $37M above consensus, with organic growth accelerating to +4% from +3% in Q4. Adjusted EPS of $1.70 (+13% Y/Y) met consensus, while operating margin expanded 70 bps to 16.7%, progressing toward the 20% target by 2027. Growth engines (20% of sales) showed strengthening momentum, with Global High-Tech delivering +25% organic growth from AI infrastructure and Life Sciences accelerating to +11% led by bioprocessing demand. Management maintained full-year EPS guidance of $8.43-$8.63 (+12% to +15%) but guided Q2 below estimates due to commodity cost pressures requiring energy surcharges. We view the High-Tech momentum as particularly significant given the multi-year AI data center runway, while the pending CoolIT acquisition reinforces ECL's end-to-end cooling capabilities. We see risk to 2H margin expansion if commodity costs remain elevated or if pricing implementation faces resistance, testing ECL's value proposition and customer relationships.
China Resources Pharmaceutical Unit Sells 1.4 Billion Yuan Bonds
China Resources Pharmaceutical (HKG:3320) unit China Resources Pharmaceutical Commercial Group completed the issue of 1.4 billion yuan of 1.65% corporate bonds in China maturing in three years, according to a Tuesday Hong Kong bourse filing.The pharma firm intends to use proceeds for production expenditures, including the replenishment of working capital, repayment of debt, and project investments.